Ensysce Biosciences (ENSC) EPS (Basic) Growth (1y) (2019 - 2025)
Ensysce Biosciences (ENSC) EPS (Basic) Growth (1y) (2019 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.23 Bn | 132.38 Bn | 2.84 Bn | 7.74% |
| 2 | Regeneron Pharmaceuticals | 86.97 Bn | 78.97 Bn | 3.93 Bn | -4.72% |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 88.81% |
| 4 | Moderna | 59.88 Bn | 54.74 Bn | 52.00 Mn | 7.59% |
| 5 | BeOne Medicines | 42.20 Bn | 37.11 Bn | 1.53 Bn | 143.95% |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 322.67% |
| 7 | BioNTech SE | 28.69 Bn | 10.30 Bn | 668.28 Mn | -147.33% |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 96.41% |
| 9 | Royalty Pharma | 27.16 Bn | 26.33 Bn | - | -16.29% |
| 10 | Ensysce Biosciences | 932,419.66 | -3.38 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -228.75% |
| Jun 30, 2025 | 76.49% |
| Mar 31, 2025 | 83.09% |
| Dec 31, 2024 | 77.99% |
| Sep 30, 2024 | 107.68% |
| Jun 30, 2024 | 77.30% |
| Mar 31, 2024 | 73.73% |
| Dec 31, 2023 | 94.96% |
| Sep 30, 2023 | 98.58% |
| Jun 30, 2023 | 98.26% |
| Mar 31, 2023 | 85.79% |
| Dec 31, 2022 | 76.22% |
| Sep 30, 2022 | 63.74% |
| Jun 30, 2022 | -303.84% |
| Mar 31, 2022 | 58.12% |
| Dec 31, 2021 | -1,699.89% |
| Sep 30, 2021 | -810.41% |
| Jun 30, 2021 | -1,367.20% |
| Mar 31, 2021 | -229.24% |
| Dec 31, 2020 | 107.42% |